Sveriges Riksbank
| Bid procedure, 2021-02-01 | |
| Bills | SWEDISH T-BILL: SE0015382064. 2021-04-21 |
| Bid date | 2021-02-01 |
| Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
| Requested volume (corresponding nominal amount) | SE0015382064: 1000 mln SEK +/-500 mln SEK |
| Highest permitted bid volume (corresponding nominal amount) | SE0015382064: 1000 mln SEK per bid |
| Lowest permitted bid volume (corresponding nominal amount) | SEK 50 million per bid |
| Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
| Delivery and payment date | 2021-02-03 |
| Delivery of bills | To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 |
Stockholm, 2021-01-29
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG5.11.2025 13:11:23 CET | Press release
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
ROCKWOOL A/S5.11.2025 13:04:11 CET | Press release
ROCKWOOL A/S – transactions in connection with share buy-back programme
Rockwool A/S5.11.2025 13:04:11 CET | Pressemeddelelse
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
Centessa Pharmaceuticals plc5.11.2025 13:00:00 CET | Press release
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
MoonLake Immunotherapeutics AG5.11.2025 13:00:00 CET | Press release
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
